| Literature DB >> 31702918 |
Sandra Röhm1,2, Benedict-Tilman Berger1,2, Martin Schröder1,2, Apirat Chaikuad1,2, Rob Winkel3, Koen F W Hekking3, Jorg J C Benningshof3, Gerhard Müller4, Roberta Tesch1,2, Mark Kudolo5, Michael Forster5, Stefan Laufer5, Stefan Knapp1,2.
Abstract
p38 mitogen-activated protein kinases are key mediators of environmental stress response and are promising targets for treatment of inflammatory diseases and cancer. Numerous efforts have led to the discovery of several potent inhibitors; however, so far no highly selective type-II inhibitors have been reported. We previously identified VPC-00628 as a potent and selective type-II inhibitor of p38α/β with few off-targets. Here we analyzed the chemical building blocks of VPC-00628 that played a key role in achieving potency and selectivity through targeting an inactive state of the kinases induced by a unique folded P-loop conformation. Using a rapid, systematic combinatorial synthetic approach, we identified compound 93 (SR-318) with excellent potency and selectivity for p38α/β, which potently inhibited the TNF-α release in whole blood. SR-318 therefore presents a potent and selective type-II inhibitor of p38α/β that can be used as a chemical probe for targeting this particular inactive state of these two p38 isoforms.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31702918 DOI: 10.1021/acs.jmedchem.9b01227
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446